Skip to content

Author

Andrew A. Lane

We have 2 of 38 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRP.

Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with multiple agents. KHSRP was the top hit, whose depletion sensitized AML cells to thera...

Qing-Yu Luo, Karley S. Whalen, Xiao-Wei Wu et al. · 0 citations
Aug 2026

Tumor-tropic E. coli engineered as living T and NK cell engagers

LIME bridged effector and tumor cells, induced transcriptional programs of T cell activation, metabolism and proliferation, and enhanced cytotoxicity across cancer cell lines and patient-derived organoids, establishing LIME as a versatile living therapeutic platform for programmable, tumor-restricted immune orchestrati...

Shao-Bo Yang, Anna Clara Bader, S. Sendker et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.